Alchemab Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
East Side Office 1.02 Kings Cross, Londo...Website
www.alchemab.comRevenue
$13.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Alchemab Therapeutics
Alchemab studies the natural antibody responses of individuals who are highly resilient to disease and identifies antibodies uniquely shared in the resilient groups and not seen in disease progressors. The targets to these antibodies are then identified and the antibodies developed into therapies for hard-to-treat diseases which do not have disease modifying approaches. Alchemab's platform integrates data mining and machine learning models of patient-derived immune responses with in vitro and in vivo drug discovery approaches to understand what keeps people well. The goal is to unlock nature's immunological response to disease and harness the company's highly evolved human immune system to find breakthrough drugs. Alchemab was founded in 2019 and is headquartered in London, UK with labs in Cambridge, UK.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alchemab Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Alchemab Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Alchemab Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Alchemab Therapeutics has new funding data
Earning: See what the market has to say on Alchemab Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Alchemab Therapeutics launches new products
Check if Alchemab Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Alchemab Therapeutics
Alchemab Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Alchemab Therapeutics
Find 3 more new buyers
Compare Similar Companies to Alchemab Therapeutics
Compare insights from companies similar to Alchemab Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Alchemab Therapeutics
$13.3M
51-200
Private
$114M
2019
N/A
Company Profile Activity
Activity Insights
Alchemab Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Alchemab Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Alchemab Therapeutics.
Alchemab Therapeutics financials insights
Gather financial insights about Alchemab Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$82M
2025
Series A
$32M
Alchemab Therapeutics Tech Stack
A closer look at the technologies used by Alchemab Therapeutics
See more technologies
Most Recent Scoops
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Open Position
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Alchemab Therapeutics News & Media
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism - Deal worth up to $415m including upfront and downstream, plus royalties on top - ATLX-1282 is the first programme out of...Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and...Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
CAMBRIDGE, England, Sept. 12, 2024 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab's Chief...Alchemab advances a novel antibody with potential in Parkinson's disease with support from The Michael J. Fox Foundation
CAMBRIDGE, England, June 6, 2024 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alchemab Therapeutics
Sign Up For FreeTo access detailed company insights
Alchemab studies the natural antibody responses of individuals who are highly resilient to disease and identifies antibodies uniquely shared in the resilient groups and not seen in disease progressors. The targets to these antibodies are then identified and the antibodies developed into therapies for hard-to-treat diseases which do not have disease... Read More
